Physician profile
Drew Schembre
NPI 1366557217
$659,365.42
in general payments reported to CMS, 2019-2025
25 companies · $57K in 2025
The $57K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $106K · 2021: $99K · 2022: $90K · 2023: $85K · 2024: $84K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $208K · Consulting Fee: $16K · Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $208,102.23 |
| Consulting Fee | $15,750.00 |
| Food and Beverage | $1,723.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $413,586.39 | 2019-2025 | Echotip Insight, Echotip |
| Cook Incorporated | $225,287.61 | 2019-2025 | |
| Neptune Medical INC. | $14,400.00 | 2023-2024 | |
| Boston Scientific Corporation | $1,282.15 | 2019-2024 | Exalt Model D, Agile Esophageal, Captivator II |
| Micro-Tech Endoscopy USA, INC. | $1,133.14 | 2019-2025 | |
| Abbvie INC. | $1,105.13 | 2019-2024 | Mavyret, Rinvoq, Linzess |
| Cook Medical LLC | $898.29 | 2019-2025 | Echotip Insight, Hemospray |
| Shockwave Medical, INC | $600.00 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Biotech, INC. | $172.49 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.67 | 2019-2022 | |
| Fujifilm Healthcare Americas Corporation | $115.70 | 2024 | Fujifilm |
| Takeda Pharmaceuticals U.S.A., INC. | $113.11 | 2019-2023 | Vpriv |
| Endogastric Solutions, INC | $98.13 | 2022 | |
| Vivus LLC | $83.89 | 2019-2020 | |
| Pentax of America, INC. | $70.23 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $59.07 | 2023 | Fibroscan |
| Conmed Corporation | $40.21 | 2023 | Conmed Generators, Conmed Biliary |
| Merck Sharp & Dohme LLC | $31.50 | 2019 | |
| Medtronic, INC. | $31.39 | 2023 | Gi Genius |
| Pfizer INC. | $29.86 | 2019 | |
| Mallinckrodt Hospital Products INC. | $25.61 | 2025 | Terlivaz |
| Daiichi Sankyo INC. | $24.58 | 2019 | |
| Qol Medical, LLC | $20.64 | 2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $20.22 | 2023 | |
| Apollo Endosurgery US INC | $4.41 | 2023 | Overstitch Endoscopic Suturing System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Schembre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.